Clinical trials: Resistant Depression, Treatment
Major Depressive Disorder, Treatment Resistant Depression
pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression
To explore the effectiveness and safety of rTMS intervention with different targets in the left prefrontal cortex defined using the pBFS method, in adult patients with moderate and severe depressive disorder.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, MDD
- Trial name
- NCT06255561
- Testing
- active rTMS stimulating
- Volunteers
- 75 people
- Sponsor
- Changping Laboratory
Depression, Dementia
Longitudinal Observational Biomarker Study
The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.
- Conditions
- Depression, Dementia, Mild Cognitive Impairment
- Trial name
- OPT-Neuro (NCT05204940)
- Testing
- Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI), Neuropsychological Data, Clinical Scales
- Where
- 5 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Centre for Addiction and Mental Health
Resistant Depression, Treatment
TReAtment With CombinedExercise in Patients With Resistant Major Depression
Major depressive disorder is one of the most prevalent and disabling mental disorders worldwide. Forty percent of people with major depressive disorder are in moderate remission, with the remainder meeting the criteria for…
- Trial name
- TRACE-RMD (NCT05136027)
- Testing
- Combined training
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- University of the Basque Country (UPV/EHU)
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Depressive Disorder
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
This study will examine whether a highly specific and powerful 5-hydroxytryptamine 2A (5-HT2A) antagonist, M100907, combined with escitalopram, is responsible for an antidepressant effect.
- Trial name
- NCT00070694
- Testing
- MDL100.907
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Treatment Resistant Depression
Antidepressant Discontinuation in Treatment Resistant Depression
The purpose of this study is to compare the effects on depressive symptoms of subjects who discontinue serotonergic antidepressants (a certain type of antidepressant, such as Prozac, that works on serotonin receptors in the…
- Trial name
- NCT03786614
- Testing
- Discontinuation of serotonergic antidepressants, Continuation of serotonergic medications
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Louisville
Major Depressive Disorder
Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study
number of center : 1 duration of study : 24 months recruitement time : 23 months Aim :Principal Evaluate the interest of maintenance rTMS in a one-year double blind randomized controlled study for TRD patients.
- Trial name
- TMS/DEP (NCT02383693)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Treatment Resistant Major Depressive Disorder
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
The purpose of this study is to determine if any improvements in depressive symptoms are maintained in the medium and longer-term (up to 3 months)
- Trial name
- ZYL-730-02 (NCT05438758)
- Testing
- Almond Therapy, Intranasal ketamine (Esketamine), Treatment as Usual
- Sponsor
- Zylorion Health
Treatment Resistant Depression
Deep Brain Stimulation in Treatment Resistant Depression
Recurrent major depressive disorder affects about 3-5% of the population. It is anticipated that by 2020, depression will be the most common cause of disability worldwide in the 18-55 age group.
- Trial name
- NCT01435148
- Testing
- Deep Brain Stimulation, implanted
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- North Bristol NHS Trust
Treatment-Resistant Depression
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PSI-TNT (NCT07211438)
- Testing
- Psilocybin
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Treatment Resistant Depression
DBS for Depression
The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression.
- Trial name
- NCT06096207
- Testing
- Medtronic SenSight Directional DBS lead
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwell Health
Major Depressive Disorder
Open Label Optimization Study
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I…
- Trial name
- OLO (NCT05819021)
- Testing
- SAINT® Neuromodulation System (NMS)
- Where
- 7 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Magnus Medical
Treatment Resistant Depression
COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression
The CoMPACT trial is a randomized double-blinded sham-controlled study aimed at testing a novel accelerated and personalized transcranial Magnetic Stimulation (TMS) treatment for patients with Treatment Resistant Depression…
- Trial name
- CoMPACT (NCT06895863)
- Testing
- MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil., Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.
- Where
- 3 sites in Denmark
- Volunteers
- 78 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Depressive Disorder, Treatment-Resistant
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
This study evaluates the efficacy and safety of ethosuximide in the treatment of refractory depressive disorder in adults. Half of participants will receive ethosuximide and escitalopram in combination, while the other half will…
- Trial name
- NCT03887624
- Testing
- Ethosuximide, Escitalopram
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang University
Depression - Major Depressive Disorder
Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin
About one in three people with major depression respond poorly to standard antidepressant treatments. This kind of depression is called treatment-resistant depression, and it can lead to long-term disability, financial…
- Trial name
- NCT07164755
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- King's College London
Major Depressive Disorder, Treatment Resistant Depression
Antidepressant Effects of Nitrous Oxide
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and…
- Trial name
- NCT05357040
- Testing
- Nitrous oxide gas for inhalation
- Where
- 2 sites in United States, Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Chicago
Prostate Cancer, Metastatic Prostate Cancer
The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients
Prostate cancer is the second most common cancer among men. Many patients experience a significantly reduced quality of life due to either the cancer itself or the side effects of treatment.
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by Radiotherapy
- Trial name
- ZMoveMent-1 (NCT07126860)
- Testing
- Structured combined resistance and aerobic training, Standard of Care
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Suicide, Depressive Disorder, Treatment-Resistant
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action
- Trial name
- NCT06511908
- Testing
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Mental Health (NIMH)